Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40. It has important physical and psychological consequences/impact in those patients. Premature ovarian failure (POF) is currently managed by non-physiological sex steroid regimens which are inadequate at optimizing uterine characteristics. Human umbilical cord mesenchymal stem cells (hUCMSCs) and human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy for POF. In this study, the safety and efficacy of hUCMSCs and hCBMNCs transplantation combined with Hormone Replacement Therapy will be evaluated in patients with Premature Ovarian Failure. Participants will be followed for an expected average of 48 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
40
Shenzhen People's Hospital
Shenzhen, Guangdong, China
RECRUITINGSerum Level of follicle-stimulating hormone
Time frame: 48 weeks after treatment
Uterine and Ovary characteristics of B ultrasound， including Uterine/Ovarian size and Blood Flow
Time frame: 48 weeks after treatment
Modified Kupperman Score
Time frame: 48 weeks after treatment
Incidence of Adverse Events and Serious Adverse Events
Time frame: 48 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.